About US
Contact us
-
Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveawayLong before Novartiswon its first approval for gene therapyZolgensma, thedrugmakerfaced questions about how it would price a one-time cure for spinal muscular atrophy, adevastating rare disease. Then2019/12/23
-
Sense or 'nonsense'? Senators blast Lilly's generic insulin, but CEO Ricks strikes backInsulin producers have faced years of negative headlines as prices and rebates rose in lockstep.So Eli Lilly tried to thwart the rebate effect with ahalf-priced version of its top insulin Humalog—and2019/12/20
-
GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial winGlaxoSmithKline's Benlysta has long enjoyed its place as the sole biologic approved to treat lupus, despite other drugmakers' forays into the field. But with competitors sniffing around, GSK is looki2019/12/20
-
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysisGENEVA—Since unveiling its Tecentriqmonotherapy win in previously untreated non-small lung cancer, Roche has faced criticism that the diagnostic test it used to identify trial patients might have inf2019/12/19
-
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancerAstraZeneca and Merck’s Lynparza is looking to become thefirstin its class of PARP inhibitors to break into the pancreatic cancer market. And a majority of FDA advisers thinks it should be—if only a2019/12/19
-
Roche's $4.3B Spark deal wins U.K. antitrust clearance, foreshadowing a similar FTC moveAfter months of delays, Roche has won the first major antitrust clearance for its proposed $4.3 billion buyout of Spark Therapeutics. Monday, the U.K.’s Competition and Markets Authority (CMA) said i2019/12/18
-
FiercePharmaPolitics—House passes Pelosi bill, Trump admin nixes biologics protections in trade pact and moreWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight notable developments that could affect howdrugmakersoperate. As the year comes to an end, lawmakers and government offic2019/12/18
-
Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansionAmarin has been on a scorching run with its fish-oil derivative Vascepa after a major cardiovascular outcomes trial last year set a possible blockbuster trajectory for the drug. Now, the FDA has vote2019/12/17
-
Intercept's NASH decision delayed by FDA, but don't panic: analystsIntercept Pharmaceuticals has been gearing up for the potential launch of its nonalcoholic steatohepatitis (NASH) med, but now its waitlooks alittle longer. While the FDA was originally due to decide2019/12/17
-
ESMO I-O: BMS zooms in on squamous lung cancer patients as it dissects Opdivo-chemo combo failureGENEVA—As Bristol-Myers Squibb continues to search for bright spots in its eyebrow-raising Opdivo-chemo combo fail from June, it’s zeroing in on the population of squamous lung cancer patients who se2019/12/16